{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:10:49Z","timestamp":1784545849835,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journalofclinicalvirology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.jcv.2015.01.023","type":"journal-article","created":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T17:39:59Z","timestamp":1422985199000},"page":"32-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses"],"prefix":"10.1016","volume":"65","author":[{"given":"Diana","family":"Kouiavskaia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaochun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Dragunsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Mirochnitchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3002-6247","authenticated-orcid":false,"given":"Konstantin","family":"Chumakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2015.01.023_bib0005","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(96)91194-0","article-title":"Sabin, Salk, or sequential?","volume":"347","author":"Hull","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2015.01.023_bib0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev.mi.41.100187.001101","article-title":"The attenuation of poliovirus neurovirulence","volume":"41","author":"Almond","year":"1987","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.jcv.2015.01.023_bib0015","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.vaccine.2009.02.071","article-title":"Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication","volume":"27","author":"Minor","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.jcv.2015.01.023_bib0020","doi-asserted-by":"crossref","unstructured":"M. Roivainen, S. Blomqvist, H. Al-Hello, A. Paananen , F. Delpeyroux , M. Kuusi , et al. Highly divergent neurovirulent vaccine-derived polioviruses of all three serotypes are recurrently detected in Finnish sewage, Euro surveillance: bulletin Europeen sur les maladies transmissibles=European communicable disease bulletin, 2010, 15, pii\/1956, http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20483108.","DOI":"10.2807\/ese.15.19.19566-en"},{"key":"10.1016\/j.jcv.2015.01.023_bib0025","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the endgame strategy for global polio eradication","volume":"59","author":"Kew","year":"2005","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.jcv.2015.01.023_bib0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.antiviral.2008.04.002","article-title":"A case for developing antiviral drugs against polio","volume":"79","author":"Collett","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jcv.2015.01.023_bib0035","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1128\/JVI.02553-10","article-title":"Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis","volume":"85","author":"Chen","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.jcv.2015.01.023_bib0040","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1073\/pnas.88.3.951","article-title":"Transgenic mice susceptible to poliovirus","volume":"88","author":"Koike","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jcv.2015.01.023_bib0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/JVI.57.1.81-90.1986","article-title":"Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site","volume":"57","author":"Blondel","year":"1986","journal-title":"J. Virol."},{"key":"10.1016\/j.jcv.2015.01.023_bib0050","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3851\/IMP1838","article-title":"Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073","volume":"16","author":"Kouiavskaia","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jcv.2015.01.023_bib0055","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1128\/AAC.00539-12","article-title":"Characterization of poliovirus variants selected for resistance to the antiviral compound V-073","volume":"56","author":"Liu","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2015.01.023_bib0060","series-title":"Manual for the Virological Investigation of Polio","author":"WHO","year":"1997"},{"key":"10.1016\/j.jcv.2015.01.023_bib0065","first-page":"497","article-title":"Maintenance and distribution of transgenic mice susceptible to human viruses: memorandum from a WHO meeting","volume":"71","author":"WHO","year":"1993","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.jcv.2015.01.023_bib0070","series-title":"Guide for the Care and Use of Laboratory Animals","author":"NRC","year":"2011"},{"key":"10.1016\/j.jcv.2015.01.023_bib0075","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/dmd.109.031310","article-title":"Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys","volume":"38","author":"Deng","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jcv.2015.01.023_bib0080","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1089\/cbr.2008.0493","article-title":"Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications","volume":"23","author":"Milenic","year":"2008","journal-title":"Cancer biother. Radiopharm."},{"key":"10.1016\/j.jcv.2015.01.023_bib0085","series-title":"Neurovirulence Test of Types 1, 2, or 3 Live Attenuated Poliomyelitis Vaccines (oral) in Transgenic Mice Susceptible to Poliovirus","author":"WHO","year":"2012"},{"key":"10.1016\/j.jcv.2015.01.023_bib0090","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S0140-6736(04)16150-3","article-title":"Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man","volume":"363","author":"MacLennan","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jcv.2015.01.023_bib0095","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1073\/pnas.1232294100","article-title":"A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity","volume":"100","author":"Pfeiffer","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jcv.2015.01.023_bib0100","series-title":"Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report","author":"Committee on development of a polio antiviral and its potential role in global poliomyelitis eradication N","year":"2006"},{"key":"10.1016\/j.jcv.2015.01.023_bib0105","first-page":"139","article-title":"Evaluation of red cross gamma globulin as a prophylactic agent for poliomyelitis","volume":"150","author":"Hammon","year":"1952","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jcv.2015.01.023_bib0110","first-page":"75","article-title":"Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies","volume":"105","author":"Minor","year":"2001","journal-title":"Dev. Biol."},{"key":"10.1016\/j.jcv.2015.01.023_bib0115","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1016\/j.vaccine.2012.10.035","article-title":"Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka","volume":"30","author":"de Silva","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jcv.2015.01.023_bib0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.antiviral.2014.05.005","article-title":"Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains","volume":"108","author":"Puligedda","year":"2014","journal-title":"Antivir. Res."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653215000372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653215000372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T11:14:10Z","timestamp":1651144450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653215000372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":24,"alternative-id":["S1386653215000372"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2015.01.023","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2015.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}